Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050687 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
A Phase 1 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00050687: Clinical Trial Phase 1 study, sponsored by Titan Pharmaceuticals.
NCT00050687 is a Phase 1 study that was terminated before completion, run by Titan Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050687, a Phase 1 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will be assessed and the levels of gallium in serum will be measured. Any effect of the drug on the cancer and any improvement in cancer-related symptoms will also be measured.
Interventions
- DRUG Gallium maltolate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Why NCT00050687 stopped before completion
NCT00050687 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Gallium maltolate is the first listed.
NCT00050687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050687 about?
NCT00050687 is a clinical study titled "Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies". This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will be assessed and the leve...
What is the current status of trial NCT00050687?
This trial is currently terminated. It is a Phase 1 study. The study started on 2001-06. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00050687?
The interventions under investigation include: Gallium maltolate (DRUG).
Who is sponsoring clinical trial NCT00050687?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia